Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?
📈 FDA approved Mounjaro to reduce heart attack or stroke risk in high-risk adults with type 2 diabetes.
🔬 Clinical study showed Mounjaro reduced major adverse cardiovascular events by 8% more than Lilly's Trulicity.
💰 Mounjaro sales surged 91% year over year to $9.94 billion in the second quarter.
🏥 The new indication allows physicians to prescribe Mounjaro for cardiovascular risk reduction alongside diabetes control.
🚀 Lilly is testing its GLP-1 medicines in conditions ranging from cardiovascular disease to liver disorders.
⚖️ Novo Nordisk previously secured similar cardiovascular-risk approvals for Wegovy and Rybelsus.
📊 The approval targets a specific high-risk population rather than all Mounjaro patients.
Bullish Signals
- FDA approved Mounjaro to reduce the risk of heart attack or stroke in adults with type 2 diabetes who face a high risk of cardiovascular events.
- Clinical evidence demonstrated that Mounjaro outperformed Trulicity, reducing the risk of major adverse cardiovascular events by 8% more than the competitor drug.
- Mounjaro sales increased 91% year over year to $9.94 billion during the second quarter, supported by higher volumes across global markets.
- The expanded indication strengthens Lilly's strategy of extending its metabolic medicines into cardiovascular care and validates their platform for regulatory approvals beyond original indications.
Full Analysis
Eli Lilly and Company (NYSE: LLY) received FDA approval for its diabetes drug Mounjaro to reduce the risk of heart attack or stroke in adults with type 2 diabetes who face a high risk of cardiovascular events. This regulatory decision expands the drug's clinical profile beyond glycemic control, allowing physicians to prescribe it based on cardiovascular benefits in addition to diabetes management.
The approval is supported by robust clinical evidence from a large head-to-head study where Mounjaro demonstrated superior efficacy compared to Lilly's own older diabetes medicine, Trulicity. Specifically, the study found that Mounjaro reduced the risk of major adverse cardiovascular events by 8% more than Trulicity, providing a compelling argument for physicians treating high-risk patients.
Commercially, Mounjaro is already experiencing substantial momentum with second-quarter sales increasing 91% year over year to $9.94 billion. While Lilly has not disclosed specific revenue expectations from this new indication, the expanded label strengthens the drug's position in a competitive market where cardiovascular benefits are increasingly valued, potentially reinforcing growth within its eligible patient population.
This development aligns with Lilly's broader strategy of extending its GLP-1 medicines into non-diabetic conditions and validating their utility in cardiovascular care. The company is also exploring these drugs for liver disorders and other metabolic conditions, using the Mounjaro approval as tangible proof that their platform can yield regulatory success beyond original indications.